Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proteome-based insights for IDH-mutant glioma classification.

Cell reports. Medicine - 17 Jan 2023

Leu Severina, Hutter Gregor, Boulay Jean-Louis

Abstract excerpt

In this issue, Bader et al.1 characterize the proteomes of diffuse glioma brain tumors by liquid chromatography mass spectrometry and classify isocitrate dehydrogenase (IDH)-mutant gliomas into two subtypes, which differ in oncogenic pathways and aerobic/anaerobic energy metabolism.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioma
Share to Isocitrate Dehydrogenase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proteome

Source

Open in PubMed Open full text

Identifiers

PMID: 36652918
DOI: 10.1016/j.xcrm.2022.100909
PMCID: PMC9873937

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proteome-based insights for IDH-mutant glioma classification.PMID 36652918Read ↗

Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status.Semantic proximity Read ↗

Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastomaSemantic proximity Read ↗

Metabolic Rewiring in Adult-Type Diffuse Gliomas.Semantic proximity Read ↗

Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.Semantic proximity Read ↗

Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.Semantic proximity Read ↗

Quantitative proteomic analysis reveals different functional subtypes among IDH-wildtype glioblastomaSemantic proximity Read ↗

Metabologenomic characterization uncovers a clinically aggressive IDH mutant glioma subtype.Semantic proximity Read ↗

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical ImplicationsSemantic proximity Read ↗

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical ImplicationsSemantic proximity Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

Cancer metabolism as a central driving force of glioma pathogenesis.Semantic proximity Read ↗

Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.